

RAUCON *BD Executive News*

Vol. 16 # 8 | 30 April 2020

Hot Company News

* Acquisition: **Aceto Corp.** completed the acquisition of **Syntor Fine Chemicals**. Syntor is an asset-light manufacturer of fine chemicals for pharmaceutical and other life sciences end markets. Syntor will operate under the name „Syntor by Aceto“. 17 Apr 2020 (www.aceto.com)

* Acquisition: **Asklepios Bio-Pharmaceutical, Inc.** has acquired **BrainVectis**, a Paris-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders. BrainVectis is particularly focused on therapies that restore brain cholesterol metabolism as a treatment for Huntington's disease and other disorders. Financial terms of the acquisition were not disclosed. 22 Apr 2020 (www.askbio.com)

* Acquisition: **Diamond Pharma Services**, a technical services and regulatory affairs consulting group, announced that its pharmacovigilance division, **Diamond PV Services**, has acquired **PharmaCentral**, a pharmacovigilance services and medical affairs business based in Dublin, Ireland. The acquisition will expand Diamond's presence in Europe and enhance the senior-level expertise within its pharmacovigilance team. 22 Apr 2020 (www.diamondbiopharm.com)

* Name change: **Highlight Therapeutics** has changed its name from **Bioncotech** with immediate effect. 17 Apr 2020 (www.highlighttherapeutics.com)

* Licensing: **iX Biopharma Ltd** has entered into a licensing agreement with **Yiling Pharmaceutical Ltd.**, for the licensing, supply and distribution of Wafesil™, a sublingual sildenafil wafer for the treatment of male erectile dysfunction,

in China. Yiling will be granted an exclusive license to market and distribute Wafesil™ in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil™ to Yiling at a supply price agreed between the parties. The initial term of the agreement is 10 years. 27 Apr 2020 (www.ixbiopharma.com/)

* Acquisition: **JCR Pharmaceuticals Co., Ltd** has completed the previously announced acquisition of **ArmaGen, Inc.**, a privately held US biopharmaceutical company headquartered in San Diego, California. 20 Apr 2020 (www.jcrpharm.co.jp/en/site/en/)

* Acquisition: **Novartis** announced today that it has completed the acquisition of **Amblyotech**, a US-based software startup, and will, in collaboration with **Ubisoft** and **McGill University**, pursue the development of the acquired digital technology for the treatment of amblyopia. 23 Apr 2020 (www.novartis.com)

* Distribution: **Oncocyte Corporation** has entered a distribution agreement with **CORE Diagnostics**, expanding the commercial availability of DetermaRx™ to India, the Middle East and Africa. DetermaRx™ is Oncocyte's treatment stratification test that identifies patients at high risk for lung cancer recurrence, who may benefit from adjuvant chemotherapy post-surgery. 23 Apr 2020 (oncocyte.com)

* Acquisition: **Orgenesis Inc.**, a biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies has completed acquiring the assets of **Tamir Biotechnology, Inc.**, including ranpirnase, TamirBio's broad spectrum anti-viral platform. The acquisition included total stock and cash consideration of approximately \$21 million. 27 Apr 2020 (www.orgenesis.com)

* Acquisition: **Orifarm Group** has entered into an agreement to purchase a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products sold in Europe from **Takeda Pharmaceutical Company Limited** for a purchase price of up to €615million. Orifarm has acquired the rights for approximately 110 pharmaceuticals including brands like Pamol, Kodimagnyl, and Zymelin, as well as 2 production sites. 24 Apr 2020 (www.orifarm.com)

* Acquisition: **Supernus Pharmaceuticals, Inc.**, a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company entered into a definitive agreement under which Supernus will acquire the CNS portfolio of **US WorldMeds**, a privately-held biopharmaceutical company. With the acquisition, Supernus adds three established and marketed products in the U.S. market with a product candidate in late-stage development. Total consideration of \$530 million consists of an upfront cash payment of \$300 million plus regulatory and commercial milestone cash payments up to \$230 million. 28 Apr 2020 (www.supernus.com)

* Name change: **Synthon Biopharmaceuticals BV**, a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless cancers and autoimmune diseases, is relaunching as **Byondis**. 16 Apr 2020 (synthonbiopharmaceuticals.com)

* Acquisition: **WuXi Biologics** has completed the acquisition deal with **Bayer** for a drug product manufacturing plant in Leverkusen, Germany. Under the asset acquisition agreement signed in January, WuXi Biologics has taken over the plant operations, purchased plant equipment

and signed a long-term building lease contract. Equipped with a state-of-the-art drug product filling line, the plant will offer sterile filling and freeze drying services of up to 10 million vials per year. 22 Apr 2020 (www.wuxibiologics.com)

BD People on the Move

* Asklepios BioPharmaceutical, Inc.: **Don Haut**, PhD, who previously served as CBO at Sherlock Biosciences and Histogenics, has been hired as new chief business officer (CBO). (Press Release 10 Apr 2020)

* Sangamo BioSciences, Inc.: **D. Mark McClung**, most recently Vice President and General Manager of Global Oncology Commercial at Amgen has been appointed as Executive Vice President and Chief Business Officer. He will oversee commercial strategic planning, alliance management and corporate and business development. (Press Release 17 Apr 2020)